0000899243-19-012052.txt : 20190503
0000899243-19-012052.hdr.sgml : 20190503
20190503172648
ACCESSION NUMBER: 0000899243-19-012052
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20190501
FILED AS OF DATE: 20190503
DATE AS OF CHANGE: 20190503
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Lowrance David L
CENTRAL INDEX KEY: 0001408498
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-32157
FILM NUMBER: 19797326
MAIL ADDRESS:
STREET 1: 422 WILLIAM WALLACE DRIVE
CITY: FRANKLIN
STATE: TN
ZIP: 37064
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Savara Inc
CENTRAL INDEX KEY: 0001160308
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 841318182
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 900 S. CAPITAL OF TEXAS HIGHWAY
STREET 2: SUITE 150
CITY: AUSTIN
STATE: TX
ZIP: 78746
BUSINESS PHONE: 512-614-1848
MAIL ADDRESS:
STREET 1: 900 S. CAPITAL OF TEXAS HIGHWAY
STREET 2: SUITE 150
CITY: AUSTIN
STATE: TX
ZIP: 78746
FORMER COMPANY:
FORMER CONFORMED NAME: Mast Therapeutics, Inc.
DATE OF NAME CHANGE: 20130312
FORMER COMPANY:
FORMER CONFORMED NAME: ADVENTRX PHARMACEUTICALS INC
DATE OF NAME CHANGE: 20030613
FORMER COMPANY:
FORMER CONFORMED NAME: BIOKEYS PHARMACEUTICALS INC
DATE OF NAME CHANGE: 20010928
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2019-05-01
0
0001160308
Savara Inc
SVRA
0001408498
Lowrance David L
6836 BEE CAVE ROAD, BUILDING III
SUITE 200
AUSTIN
TX
78746
0
1
0
0
Chief Financial Officer
Common Stock
2019-05-01
4
M
0
3800
1.51
A
3800
D
Common Stock
2019-05-01
4
S
0
3800
10.7639
D
0
D
Common Stock
2019-05-02
4
M
0
3700
1.51
A
3700
D
Common Stock
2019-05-02
4
S
0
3700
10.8172
D
0
D
Employee Stock Option (right to buy)
1.51
2019-05-01
4
M
0
3800
0.00
D
2026-10-25
Common Stock
3800
84384
D
Employee Stock Option (right to buy)
1.51
2019-05-02
4
M
0
3700
0.00
D
2026-10-25
Common Stock
3700
80684
D
The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 26, 2018.
The price is a weighted average sale price. The sale prices ranged from $10.55 to $11.10. The reporting person undertakes to provide Savara Inc., any security holder of Savara Inc., or the staff of the Securities and Exchange Commission, upon receipt of a request, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.
The price is a weighted average sale price. The sale prices ranged from $10.68 to $11.02. The reporting person undertakes to provide Savara Inc., any security holder of Savara Inc., or the staff of the Securities and Exchange Commission, upon receipt of a request, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.
The shares subject to the option vest and become exercisable in sixteen equal installments on each quarterly anniversary of October 25, 2016, subject to the reporting person's continued service with Savara Inc.
/s/ David Lowrance
2019-05-03